
Auris Medical Holding Ltd. EBITDA 2011-2026 | EARS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Auris Medical Holding Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -5.28 M | -7.25 M | -10.8 M | -24.3 M | -30.2 M | -30.8 M | -21.3 M | -14.5 M | -4.6 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.6 M | -30.8 M | -16.6 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 3.63 | - | $ 1.08 B | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
199 M | $ 16.54 | - | $ 3.94 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
57 M | $ 19.86 | - | $ 2.51 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.83 | - | $ 4.53 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Burford Capital Limited
BUR
|
242 M | $ 8.37 | - | $ 1.36 B | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Cabaletta Bio
CABA
|
-73.2 M | $ 3.43 | 5.54 % | $ 4.01 M | ||
|
ANI Pharmaceuticals
ANIP
|
68.3 M | $ 76.53 | - | $ 1.48 B | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-49.5 M | - | - | $ 521 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 24.69 | - | $ 3.02 B | ||
|
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.82 | - | $ 5.52 M | ||
|
Axsome Therapeutics
AXSM
|
-166 M | $ 164.08 | - | $ 8.16 B | ||
|
Champions Oncology
CSBR
|
6.15 M | $ 6.0 | - | $ 82 M | ||
|
BridgeBio Pharma
BBIO
|
-518 M | $ 66.54 | - | $ 12.7 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-11.5 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B | ||
|
Equillium
EQ
|
-14.4 M | $ 1.75 | -1.13 % | $ 60.8 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Eton Pharmaceuticals
ETON
|
-291 K | $ 17.53 | - | $ 450 M | ||
|
Evogene Ltd.
EVGN
|
-31 M | $ 0.84 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
901 M | $ 41.69 | - | $ 11.3 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.81 | - | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
489 M | $ 60.43 | - | $ 11.6 B |